It is an essential liquid for MRI examinations.
Injected into the body, the contrast product opacifies elements of the body to make them visible on the images recorded during the examination.
The French company Guerbet has just obtained the green light from the FDA, the American health authority, for the marketing of a new innovative contrast product, Elucirem, which requires half the amount of gadolinium.
An asset, while this metal being part of the rare earths causes in some cases slight side effects (nausea, headaches, dizziness…).
Reducing the dose of gadolinium is part of the recommendations of health authorities as well as learned radiology societies.
“We achieve the same image quality and with a significant benefit for patients,
rejoices David Hale, CEO of Guerbet.
There had been no major innovation in this market for thirty years.
And it was already Guerbet at the time.”
It has been nine years since the French company…
This article is for subscribers only.
You have 69% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT